Pilot Bravo Capsule Study

• Research type

  Research Study

• Full title

  A randomised, 4 way crossover, double blind, placebo controlled pilot study in patients with reflux symptoms, to assess suppression of gastro-oesophageal reflux by ‘Gaviscon Double Action Mint ’ using the Bravo system

• IRAS ID

  120719

• Contact name

  Pui M Leung

• Sponsor organisation

  Reckitt Benckiser Healthcare (UK) Ltd.

• Eudract number

  2012-004109-28

• ISRCTN Number

  To be registered

• Research summary

  Reckitt-Benckiser Healthcare Ltd. wants to gain more information on the way Gaviscon Double Action Liquid affects reflux of stomach acid and therefore acidity in the oesophagus. We will be using a small capsule that will be temporarily attached to the wall of the oesophagus and will be transmitting the level of acidity in your oesophagus to a recorder that will be worn around your waist.

• REC name

  Wales REC 2

• REC reference

  13/WA/0016

• Date of REC Opinion

  18 Jan 2013

• REC opinion

  Favourable Opinion